Manuscripts for submission to Anatomy & Cell Biology (Anat Cell Biol, ACB) should be prepared according to the following instructions. For issues not addressed in these instructions, the author is referred to the "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals" (http://www.icmje.org/recommendations/); International Committee of Medical Journal Editors [ICMJE]).

The journal adheres to the ethical guidelines for research and publication described in Guidelines on Good Publication (http://publicationethics.org/resources/guidelines), the ICMJE Guidelines (http://www.icmje.org), and Principles of Transparency and Best Practice in Scholarly Publishing (joint statement by COPE, DOAJ, WAME, and OASPA, https://publicationethics.org/news/principles-transparency-and-bestpractice-scholarly-publishing-revised-and-updated). ACB follows the international standards for editors and authors press release, https://publicationethics.org/guidance/Guidelines and the COPE flowcharts, https://publicationethics.org/guidance/Flowcharts.

1. Authorship and Contributorship

To be listed as an author one should have contributed substantially to all four categories established by the International Committee of Medical Journal Editors (ICMJE): 1) substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; 2) drafting the work or reviewing it critically for important intellectual content; 3) final approval of the version to be published; 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors should meet conditions of 1, 2, 3, and 4. The ICMJE further states that acquisition of funding, the collection of data, or general supervision of the research group, by themselves, do not justify authorship. Individuals who have contributed substantially to some but not all of the four categories, or in other areas, should be listed in the Acknowledgements. The ACB recommends that authors submit a short description of all contributions to their manuscript. Each author's contribution should be described in brief, to appear immediately before the references.
Generative artificial intelligence (AI) including language models, chatbots, image creators, machine learning, or similar technologies do not qualify for authorship. The technologies listed above may be used in enhancing readability and language accuracy in scientific writing. The responsibility for the manuscript's integrity ultimately rests with the human authors, and the authors employing generative AI tools in manuscript preparation are required to disclose their use in the Acknowledgements section. Such disclosure should detail the specific tools used, including the model name, version, and manufacturer, and explain the capacity in which they were employed. Should the use of AI extend beyond language enhancement, the methods and tools used must be detailed in the Materials and methods section as a formal part of the research design.

2. Conflict of Interest

A conflict of interest may exist when an author (the author's institution or employer) has financial or personal relationships or affiliations that could bias the author's decisions of the manuscript. Authors are expected to provide detailed information about all relevant financial interests and relationships or financial conflicts, particularly those present at the time the research was conducted and through publication, as well as other financial interests (such as patent applications in preparation), that represent potential future financial gain. All disclosures of any potential conflicts of interest, including specific financial interests and relationships and affiliations (other than those affiliations listed in the title page of the manuscript) relevant to the subject of their manuscript will be disclosed by the corresponding author on behalf of each co-author, if any, as part of the submission process. Likewise, authors without conflicts of interest will be requested to state so as part of the submission process. If authors are uncertain about what constitutes relevant financial interests or relationships, they should contact the editorial office.

3. Animal and Human Subjects

Clinical research should be done in accordance with the Ethical Principles for Medical Research Involving Human Enacted March 2010 Revised September 2023 Subjects, as outlined in the Helsinki Declaration of 1975 (revised 2013; https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/). Clinical studies that do not comply with it will not be considered for publication. For human subjects, personal information such as patients' names, individual registration numbers, dates of birth, or other private matters should not be disclosed. In cases of animal experiments, it should be stated clearly that the processes complied with regulations of the authors' institution(s) or national research committee related to breeding and using laboratory animals or the NIH Guide for the Care and Use of Laboratory Animals. Copies of the protocol approved by Institutional Review board (IRB) or Institutional Animal Care and Use Committee (IACUC) should be available for review if necessary.
ACB condemns unethical treatment of subjects in laboratory research, both human and animal. The report of any research involving human beings or experimental subjects must be conducted in accordance with the local or national requirements approved by their Institutional Review Board or Animal Research Committee. Manuscripts that do not comply with acceptable standards for the humane treatment of vertebrate animals will not be considered for publication.

4. Registration of the Clinical Research and Data Sharing Policy

Any research that deals with clinical trial should be registered to the primary national clinical trial registration site such as http://cris.nih.go.kr/cris/index.jsp, or other sites accredited by World Health Organization or ICMJE (http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html).
This journal follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors”. The ICMJE’s policy regarding trial registration is explained at http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record.

5. Originality and Duplicate Publication

All submitted manuscripts should be original and should not be considered by other scientific journals for publication at the same time. Any part of the accepted manuscript should not be duplicated in any other scientific journal without the permission of the Editorial Board. If duplicate publication related to the papers of this journal is detected, the authors will be announced in the journal and their institutes will be informed, and there also will be penalties for the authors.

6. Plagiarism

Authors must obtain permission to reproduce any copyright material, and include an acknowledgement of the source in their articles. Authors should be aware that the unreferenced use of the published and unpublished ideas, writing, or illustrations of others, from whatever source (including research grant applications), or submission of a complete paper under 'new' authorship in the same or a different language, constitutes plagiarism.

1. Review Articles

Review articles shall be limited to invited review articles, selected by the Editorial Board as addressing a significant theme from areas relevant to cell biology based on anatomy and whose authors were selected and referred on the basis of articles published in this or other journals. The submitted manuscripts will be decided for publication after peer review with the supervision of the journal’s Editorial Board. The length of the manuscript should not exceed 3,500 words excluding cover letter, tables, figures, and references. The reference list should not exceed 100. However, if necessary, the length of the manuscript, number of figures, tables, and references can be added in accordance with the decision of the editorial committee.

2. Original Articles

The sections of the manuscript for original articles should be organized in the following order: 1) title page, 2) abstract and keywords, 3) introduction, 4) materials and methods, 5) results, 6) discussion, 7) ORCID 8) author contributions 9) conflicts of Interest, 10) funding 11) acknowledgements (if necessary), 12) references, 13) tables, 14) figures, and 15) figure legends.
The manuscript, in English, must be in double-spaced typing on pages of A4 size (21×29 cm; leaving margins of 2 cm on the left, right, top, and bottom). Use 12 point Times New Roman style font. All manuscript pages are to be numbered consecutively, beginning with the abstract as page 1.

3. Case Reports

Case reports shall address states of disease that have not been reported before or have rarely been seen, and those that have already been reported on but are distinctively different from cases in previous reports may be submitted to this journal. The manuscript should not exceed 1,500 words excluding cover letter, tables, figures, and references. A maximum of 15 references is permitted; all references should pertain to the featured case. The abstract, unlike those for original articles, should have only one paragraph, no more than 150 words, and be written in English. The cover letter should include the phrase "Case Report," and the report's title should not include "... case" or "A case of." The case report should be organized in the following order: 1) title page, 2) abstract and keywords, 3) introduction (without an 'introduction' heading), 4) case report(s) (case I, case II...), 5) discussion, 6) acknowledgements (if necessary), 7) references, 8) tables, 9) figures, and 10) figure legends. The page numbers in the manuscript should be counted from the title page and appear in the center of the bottom of each page.
The keywords should be in accordance with those for original articles. The introduction shall briefly describe the general background and significant findings related to the relevant case. The discussion shall focus on what the case report emphasizes, and end with a conclusion summarizing the main points that does not have a separate 'conclusion' heading.

All authors must submit the manuscript online (http://www.acbjournal.com/submission/Login.html) only. The corresponding author must read all the sections of the "Guide for Authors." The corresponding author should upload the manuscript during the article submission process.
Authors for whom English is a second language may choose to have their manuscript professionally edited before submission to improve the proper usage of language. A list of independent suppliers of editing services can be found at website for English Correction provided by KAMJE (http://www.kamje.or.kr/).
If the corresponding author is new to the system, he or she must create a profile by clicking on the "create a new account" link, which will guide the user through the process of creating a profile. Once this is completed, the new user should return to the main page and log in. The option to submit a manuscript should be available at the top of the screen. ACB Bench>Press will give authors instructions on submitting their paper. Manuscript submission online can be accepted either MS Word file format DOC or DOCX.
Figures for review should be uploaded separately as JPEG or TIFF files. On acceptance, authors will be required to provide high resolution graphics files (only TIFF files are acceptable for publication).
A covering letter or comments to the Editor in Chief should be submitted when prompted online. The covering letter must contain the following: 1) manuscript title; 2) author(s) name(s); 3) type of manuscript; 4) brief statement of the significance of the paper; 5) optional suggested reviewers (names, addresses, and e-mail).
The ACB holds the copyright on all material appearing in this journal. The corresponding author must check the appropriate boxes and sign the Copyright Transfer Agreement Form on behalf of the other authors, which transfers copyright to the ACB.
Any questions during this process should be directed to the Editorial Office.

1. Editorial Board

The Editorial Board deals with acceptance and editing of manuscripts. Articles may be accepted conditionally with minor or major revisions required. The Editorial Board reserves the right to make minor corrections that do not affect the content communicated by the paper. Submission of data can be required from the author(s) by reviewer request according to the decision taken by the Editorial Board.

2. Reviewing and Publication of Manuscripts

All the submitted manuscripts will undergo the peer review process by two or three professionals selected by the Editor in Chief, and publication decisions will solely depend on the Editorial Board including section editors and the Editor in Chief. If reviewers differ in their assessment of a paper, the final decision on the relevant manuscript shall be made after an additional editorial board review.
A selected manuscript's place in the publication queue shall be decided based on its type and the date when its publication was approved by the Publication Committee

3. Conditions of Acceptance

Manuscripts are accepted on the understanding that they will not be published elsewhere in any form without the prior consent of the Editor in Chief of ACB. An author's material will not be passed to the publisher without receipt of: 1) a covering letter documenting any revisions requested by the editor; 2) a signed exclusive license form; 3) 600 dpi TIFF files for all final artwork. Low resolution artwork submitted for review is not suitable for print or online publication.

4. Article Tracking

Author Services enables authors to track their article - once it has been accepted - through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The author will receive an e-mail with a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript. Details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more are available on our website.

5. Revisions

Revised manuscripts must be submitted in their final form, within 5 weeks of the authors being notified of conditional acceptance (pending satisfactory revision). Resubmissions after this time will be considered as new. When submitting a revised manuscript, all changes should be indicated with red font and underlined. Deletions need not be indicated within the article itself but should be noted in the author responses to reviewers.
If the "track changes" function of a word processing program is used to show additions and deletions, all changes must be "accepted" before submitting the clean revised version. Once the changes are accepted, the track changes function should be deactivated before saving and uploading the file.
Two versions - one showing "corrections" and a "clean" final version - should be submitted.

1. Accepted Manuscripts

Accepted manuscripts will be scheduled for publication as quickly as possible.
Correspondence concerning the copy editing, proofreading, and the production of accepted manuscripts should be addressed to the Publisher online (edit@medrang.co.kr).
The designated corresponding author will receive notification of availability of page proofs by e-mail. Corrections should be returned to the Publisher online (edit@medrang.co.kr).

2. Proofs

E-mail notification that an author's work is in proof and ready for publication will be sent from the ACB e-proofing website. Further instructions will be sent in a PDF file with the upload notification e-mail. Acrobat Reader software, which is available for free download, is required in order to read this file. The corresponding author should arrange for a colleague to make corrections to the proofs in the case of his or her absence. Major alterations at the proof stage are discouraged and the costs of developing new proofs will be charged to the author and it may delay publication.

3. Article Processing Charge

There is no article processing charge of author-side.

Editorial office:
Department of Oral Biology, Yonsei University College of Dentistry, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-2228-3067 / Fax: +82-2-393-8076
E-mail: hjk776@yuhs.ac